Kojima Koji, Ignotz Ronald A, Kushibiki Toshihiro, Tinsley Kevin W, Tabata Yasuhiko, Vacanti Charles A
Laboratory for Tissue Engineering and Regenerative Medicine, Brigham & Women's Hospital, Harvard Medical School, Worcester, MA 02115, USA.
J Thorac Cardiovasc Surg. 2004 Jul;128(1):147-53. doi: 10.1016/j.jtcvs.2004.02.038.
The purpose of this study was to evaluate the feasibility of using autologous sheep marrow stromal cells cultured onto polyglycolic acid mesh to develop helical engineered cartilage equivalents for a functional tracheal replacement. We also explored the potential benefit of local delivery of transforming growth factor beta 2 with biodegradable gelatin microspheres.
Bone marrow was obtained by iliac crest aspiration from 6-month-old sheep and cultured in monolayer for 2 weeks. At confluence, the cells were seeded onto nonwoven polyglycolic acid fiber mesh and cultured in vitro with transforming growth factor beta 2 and insulin-like growth factor 1 for 1 week. Cell-polymer constructs were wrapped around a silicone helical template. Constructs were then coated with microspheres incorporating 0.5 microg transforming growth factor beta 2. The cell-polymer-microsphere structures were then implanted into a nude rat. On removal, glycosaminoglycan content and hydroxyproline were analyzed in both native and tissue-engineered trachea. Histologic sections of both native and tissue-engineered trachea were stained with hematoxylin and eosin, safranin-O, and a monoclonal anti-type II collagen antibody.
Cell-polymer constructs with transforming growth factor beta 2 microspheres formed stiff cartilage de novo in the shape of a helix after 6 weeks. Control constructs lacking transforming growth factor beta 2 microspheres appeared to be much stiffer than typical cartilage, with an apparently mineralized matrix. Tissue-engineered trachea was similar to normal trachea. Histologic data showed the presence of mature cartilage. Glycosaminoglycan and hydroxyproline contents were also similar to native cartilage levels.
This study demonstrates the feasibility of engineering tracheas with sheep marrow stromal cells as a cell source. Engineering the tracheal equivalents with supplemental transforming growth factor beta 2 seemed to have a positive effect on retaining a cartilaginous phenotype in the newly forming tissue.
本研究旨在评估将自体绵羊骨髓基质细胞接种于聚乙醇酸网片上,以构建螺旋状工程化软骨等效物用于功能性气管替代的可行性。我们还探讨了用可生物降解的明胶微球局部递送转化生长因子β2的潜在益处。
从6月龄绵羊的髂嵴抽取骨髓,进行单层培养2周。细胞汇合后,接种到非织造聚乙醇酸纤维网片上,并在体外与转化生长因子β2和胰岛素样生长因子1共同培养1周。细胞 - 聚合物构建体包裹在硅胶螺旋模板上。然后用含有0.5微克转化生长因子β2的微球包被构建体。接着将细胞 - 聚合物 - 微球结构植入裸鼠体内。取出后,分析天然气管和组织工程气管中的糖胺聚糖含量和羟脯氨酸含量。对天然气管和组织工程气管的组织学切片进行苏木精 - 伊红染色、番红O染色以及抗II型胶原单克隆抗体染色。
含有转化生长因子β2微球的细胞 - 聚合物构建体在6周后形成了螺旋形状的新生硬软骨。缺乏转化生长因子β2微球的对照构建体似乎比典型软骨更硬,基质明显矿化。组织工程气管与正常气管相似。组织学数据显示存在成熟软骨。糖胺聚糖和羟脯氨酸含量也与天然软骨水平相似。
本研究证明了以绵羊骨髓基质细胞作为细胞来源构建气管的可行性。用补充的转化生长因子β2构建气管等效物似乎对在新形成组织中保留软骨表型有积极作用。